guluronic acid

Guluronic acid (specifically α-L-guluronic acid, also known as G2013) is a uronic acid structurally related to mannuronic acid and commonly found in polysaccharides such as alginate. It has been developed and patented as a novel anti-inflammatory drug with immunomodulatory properties. Preclinical and clinical studies indicate that guluronic acid (G2013) acts by reducing the gene expression and activity of cyclooxygenase enzymes COX-1 and COX-2, suggesting its mechanism is similar to nonsteroidal anti-inflammatory drugs (NSAIDs). In a phase II clinical trial for secondary progressive multiple sclerosis (SPMS), oral administration of guluronic acid demonstrated good safety, tolerability, and no significant adverse effects compared to conventional treatments. The compound has shown promise in experimental models of multiple sclerosis and other inflammatory diseases[5][8][4].

Other names

α-L-guluronic acid